Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.40
Bid: 3.30
Ask: 3.50
Change: 0.00 (0.00%)
Spread: 0.20 (6.061%)
Open: 3.40
High: 3.40
Low: 3.30
Prev. Close: 3.40
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

Mon, 05th Feb 2024 14:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

ECR Minerals PLC - Australia-focused gold exploration company - Drills seven successful holes, and says there is evidence of anomalous gold with the best result being 23.39 grammes per tonne of gold over metre. Says the best sample still has 4.7 g/t of gold in the tailings of the initial results. Chief Executive Officer Mike Whitlow says: "This is an encouraging start to our examination of Davey Road. Based on ECR's work historically in this region, our expectation was that any gold would be both course and confined within narrow veins. These preliminary results support this assumption and consequently analysis of the bulk samples is a necessary step before we have a full picture of the geology. There is plenty so far to be pleased with but these results are indicative only and we look forward to gaining a better understanding of the location once full testing is complete."

----------

FireAngel Safety Technology Group PLC - Coventry, England-based developer and supplier of home safety products - Expects to report sales for 2023 of approximately GBP41.0 million, down 29% from GBP57.5 million a year ago. Says UK Trade division performance suffered from the restructuring in its sales team. International sales also remained comparatively depressed in the second half of 2023, it says, as new legislation in Benelux in 2022, which had led to a surge in customer demand in the region for products during 2022, was not carried into 2023 as customers looked to reduce inventory intake.At December 31, FireAngel had net debt of GBP3.1 million, down from GBP4.8 million in 2022.

----------

Smarttech247 Group PLC - Cork, Ireland-based artificial intelligence-enhanced cybersecurity services provider - Expands its NoPhish email security tool to Google Mail users. Says NoPhish employs advanced analysis algorithms to evaluate the content and legitimacy of the reported emails, offering instant feedback to the user. In cases where an email is identified as suspicious or malicious, NoPhish takes proactive measures by automatically removing the email from the user's inbox, thereby mitigating the risk of accidental exposure to harmful content. CEO Raluca Saceanu says: "We are delighted to bring NoPhish to Google Mail users. Our mission has always been to provide cutting-edge, user-friendly cybersecurity tools and by making NoPhish available on one of the world's most widely used email platforms, we are taking a significant step towards making the digital world safer for everyone. The integration signifies major advancement in email security, as Google Mail's extensive user base can now benefit from Smarttech247's phishing detection and response technology. This expansion is part of our ongoing efforts to adapt and evolve in the face of ever-changing cyber threats, ensuring users across various platforms can enjoy a safer email experience."

----------

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious diseases - Says Sally Adams resigns as chief development officer, while Callum Scott is named as the new head of development, effective immediately. Says Adams will remain with the company part time for six months to ensure a "smooth and effective transition of responsibilities."

According to Scancell, Scott has more than 15 years of experience in vaccine research and development. Previously, he held the role of technical transfer & formulation development manager at biotech firm Allergy Therapeutics PLC. CEO Lindy Durrant says: "Firstly, on behalf of the Scancell board, I would like to express our sincere gratitude to Sally for her expertise and support over the last 15 years, both on the board and leading clinical development. She has been instrumental in establishing a highly motivated development team and has worked tirelessly to bring our highly differentiated and valuable cancer vaccines through to the clinic. We wish her all the best for the future. "I would also like to warmly welcome Callum to Scancell. His understanding of the challenges involved in developing, registering, and commercialising novel biologics will be of great value to Scancell as we continue to develop our lead assets SCIB1 and Modi-1 through later stage clinical development."

----------

Alliance Pharma PLC - Chippenham, England-based distributor of consumer healthcare brands and prescription medicines - Appoints Camillo Pane as chair, effective February 19. He will be replacing Jo LeCouilliard. "Jo and the board feel that it is now appropriate for her to step down from the board and to appoint a new chair, with strong international consumer healthcare experience, to lead the company through its next strategic phase, focusing on organic growth through marketing and innovation," says Alliance Pharma. Senior Independent Director Richard Jones says: "On behalf of the Alliance board and the company I would like to thank Jo for her significant contribution to Alliance over the past five years and wish her well for the future. We look forward to Camillo joining the board as chair and harnessing his wide-ranging consumer healthcare experience to further enhance and develop our group strategy. In the meantime, the board remains focused on creating value for our shareholders by investing in growth whilst carefully managing our cost base."

----------

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
26 Sep 2016 14:24

Allergy Therapeutics swings to FY loss on R&D spend

(ShareCast News) - Allergy Therapeutics posted a rise in revenue for the year to the end of June but said it swung to a loss as it ramped up its spending on research and development. Revenue rose 12% from 2015 to £48.5m but the company reported a pre-tax loss of £12.1m versus a profit of £654,000 th

Read more
26 Sep 2016 09:46

Numis reiterates 'buy' on Allergy Therapeutics after full year results

(ShareCast News) - Numis reiterated a 'buy' rating and target price of 37p on Allergy Therapeutics on Monday after the company reported its full year results. Allergy reported a 19% increase in revenue at constant currency to £51.5m in the year ended 30 June as it grew market share in its main Europ

Read more
13 Jul 2016 08:43

Allergy Therapeutics Expects Revenue Rise Despite Euro Weakening

Read more
8 Jul 2016 14:02

Allergy Therapeutics sees good results from Acarovac Plus

(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics published a one-year follow up study of patients using Acarovac Plus on Friday, in the peer-review journal Immunotherapy. The AIM-traded firm's Acarovac Plus product was described as a microcrystalline tyrosine-adsorbed, house

Read more
8 Jul 2016 07:26

Allergy Therapeutics Welcomes Positive Follow-Up Results For Acarovac

Read more
27 Jun 2016 09:51

WINNERS & LOSERS SUMMARY: easyJet And Foxtons In Post-Brexit Warnings

Read more
27 Jun 2016 09:06

Allergy Therapeutics Sees Delayed US Market Launch For GrassMATAMPL

Read more
10 Jun 2016 07:41

Allergy Therapeutics Appoints Skyepharma's Wykeman As Finance Director

Read more
9 May 2016 06:57

Allergy Therapeutics Gets Positive Birch Pollen Treatment Results

Read more
5 Apr 2016 08:12

NetScientic Poaches New Finance Boss From Allergy Therapeutics

Read more
17 Mar 2016 09:08

Allergy Therapeutics Finance Director Ian Postlethwaite Resigns

Read more
10 Mar 2016 09:33

BROKER RATINGS SUMMARY: Jefferies Starts Metro Bank With Buy Rating

Read more
8 Mar 2016 10:59

Allergy Therapeutics Profit Drops On Higher Costs As Revenue Edges Up

Read more
18 Feb 2016 08:08

Allergy Therapeutics Completes Enrolment For Grass Pollen Drug Study

Read more
13 Jan 2016 09:38

Allergy Therapeutics Revenue Up In First Half, Full Year Seen In Line

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.